Angus Dalgleish - F1000 Section Head (since 18 February 2008)
Department of Oncology/Cellular and Molecular Medicine, St George's Hospital, University of London, London, UK
BIOGRAPHY
Professor Angus Dalgleishhttp://www.sgul.ac.uk/about-st-georges/divisions/faculty-of-medicine-and-biomedical-sciences/cellular-molecular-medicine/section-for-clinical-medicine-1/staff-profiles/professor-angus-dalgleish?searchterm=Angus+Dalgl
The main focus of our work is the use of novel approaches to the treatment of cancer. Previous work on HIV pathogenesis-which is still an active project- showed that AIDS requires activation of the immune response by HIV and not just viral replication. The similarity with the presence of chronic inflammation as a precursor to cancer has highlighted the role of the immuneresponse (which although activated results in cell mediated suppression,) and presence of angiogenesis. We have both preclinical and clinical vaccine programmes, one of which have spun out a company -Onyvax.ltd. which has excellent phase 2 trial results for a prostate cancer vaccine. Currently our main focus is developing effective dendritic cell approaches for a number of cancers. the main trial is currently for melanoma but others are being planned with the RMH and UCL.
The similarities between the immune responses in AIDS and cancer led to further research on thalidomide and the start of an analogue programme by Celgene which has just led to the successful confirmation of revlimid (CC-5013) as the most active agent in myeloma.
Current funding is from the Cancer Vaccine Institute, the Fisher family Trust,the Sobell Trust and a programme grant from Celgene.